Follicular lymphoma (FL) is an incurable indolent B cell malignancy characterized in the majority of cases by the t(14;18) translocation. While the mutational landscape of the coding genome is nearing completion, less is known about the characteristics of its noncoding genome. Our expectation is that the distribution of noncoding mutations will be non-random, determined by epigenomics features, such as chromatin modification and accessibility. Our strategy is therefore to integrate whole genome epigenomic marks and mutations in order to enrich for variants with regulatory potential and identify unique mutational processes specific to thesecis-regulatory elements (CREs).Allele-specific expression (ASE) patterns allow further refinement to re...
We thank Drs. Tim Huang, Kenneth Nephew and Phillip Buckhaults for critical review of this manuscrip...
<div><p>The processes of somatic hypermutation (SHM) and class switch recombination introduced by ac...
Follicular lymphoma (FL) is an indolent disease, but 30-40% of cases undergo histologic transformati...
Follicular lymphoma (FL) is an incurable indolent B cell malignancy characterized in the majority of...
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgk...
Substantial progress has been achieved in characterizing protein coding (PC) regions for cancer geno...
Background: With the rapid increase of whole-genome sequencing of human cancers, an...
Follicular lymphoma (FL) is the second most common lymphoma in the United States. Although it is gen...
Follicular lymphoma (FL) is morphologically and clinically diverse, with mutations in epigenetic reg...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Progn...
Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a dist...
Follicular lymphoma (FL) is incurable with conventional therapies and has a clinical course typified...
PhDFollicular lymphoma (FL) is an incurable indolent non-Hodgkin’s lymphoma (NHL) that behaves heter...
Follicular lymphoma is an incurable malignancy, with transformation to an aggressive subtype represe...
The contribution of mutations in regulatory regions to tumorigenesis has been the subject of many re...
We thank Drs. Tim Huang, Kenneth Nephew and Phillip Buckhaults for critical review of this manuscrip...
<div><p>The processes of somatic hypermutation (SHM) and class switch recombination introduced by ac...
Follicular lymphoma (FL) is an indolent disease, but 30-40% of cases undergo histologic transformati...
Follicular lymphoma (FL) is an incurable indolent B cell malignancy characterized in the majority of...
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgk...
Substantial progress has been achieved in characterizing protein coding (PC) regions for cancer geno...
Background: With the rapid increase of whole-genome sequencing of human cancers, an...
Follicular lymphoma (FL) is the second most common lymphoma in the United States. Although it is gen...
Follicular lymphoma (FL) is morphologically and clinically diverse, with mutations in epigenetic reg...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Progn...
Follicular lymphoma (FL) is a B-cell non-Hodgkin lymphoma of germinal center (GC) origin with a dist...
Follicular lymphoma (FL) is incurable with conventional therapies and has a clinical course typified...
PhDFollicular lymphoma (FL) is an incurable indolent non-Hodgkin’s lymphoma (NHL) that behaves heter...
Follicular lymphoma is an incurable malignancy, with transformation to an aggressive subtype represe...
The contribution of mutations in regulatory regions to tumorigenesis has been the subject of many re...
We thank Drs. Tim Huang, Kenneth Nephew and Phillip Buckhaults for critical review of this manuscrip...
<div><p>The processes of somatic hypermutation (SHM) and class switch recombination introduced by ac...
Follicular lymphoma (FL) is an indolent disease, but 30-40% of cases undergo histologic transformati...